Predictive factors for delayed high-dose methotrexate elimination: A practical issue for diffuse large B-cell lymphoma patients

Margot Vattaire-Hervé, Antoine Le Bozec, Justine Clarenne, Guillaume Cohet, Violaine Lepage, Chloé Gossery, Elise Michelet-Huot, Anne Quinquenel, Isabelle Madelaine, Eric Durot, Florian Slimano

Journal of Oncology Pharmacy Practice

Published online on May 06, 2025

Abstract

Journal of Oncology Pharmacy Practice, Ahead of Print.
PurposeThe high-dose methotrexate (HD-MTX) regimen (>1 g/m2) is the standard of care for preventing and managing central nervous system (CNS) invasion in diffuse large B-cell lymphoma (DLBCL). Delayed elimination of HD-MTX can lead to severe toxicity. ...